Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04969965




Registration number
NCT04969965
Ethics application status
Date submitted
13/07/2021
Date registered
21/07/2021
Date last updated
28/06/2022

Titles & IDs
Public title
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations
Scientific title
A Single Dose Phase 1 Study in Healthy Participants to Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations
Secondary ID [1] 0 0
EQ143-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
NSCLC 0 0
Healthy Volunteers 0 0
Pharmacokinetics 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - aumolertinib

Experimental: Aumolertinib - single dose oral 110mg of aumolertinib


Treatment: Drugs: aumolertinib
EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To compare the concentration (called PK) of EQ143 in the blood following a single oral administration in adult, healthy participants.
Timepoint [1] 0 0
Pharmacokinetic (PK) blood sampling will be conducted at pre-dose (within 1 hour prior to dosing) on day 1at an interval of 1 and 2 hours and Day 2, Day 3, Day 4, Day 5, Day 6, and Day 8 post-dose and at the end of study (EOS) visit (10 days post-dose).
Secondary outcome [1] 0 0
To evaluate the safety and tolerability of EQ143 following a single oral administration in adult, healthy, Caucasian, Black or African American, Hispanic or Latino, and ethnic Chinese populations.
Timepoint [1] 0 0
12-38 Days

Eligibility
Key inclusion criteria
To be eligible for this study, a participant has to meet all of the following inclusion
criteria:

1. Participant self-reports as being of one of the following racial or ethnic groups:

1. being of non-Chinese, European descent

2. having origins in any of the black racial groups of Africa

3. being of Cuban, Mexican, Puerto Rican, Cuban, South or Central American, or other
Spanish culture or origin, regardless of race

4. having two Han Chinese biological parents;

2. Is capable of giving informed consent and complying with study procedures;

3. Healthy male or female participants, between the ages of 18 and 65 years, inclusive at
the time of informed consent;

4. Body mass index (BMI) of 18.0 to 34.9 kg/m2 inclusive and body weight not less than 50
kg;

5. Female participants must have a negative serum pregnancy test result at Screening and
negative urine pregnancy test at admission to the study site, are not currently
breastfeeding, and meet one of the following criteria:

1. Surgically sterile for at least 3 months prior to Screening by one of the
following means:

- Bilateral tubal ligation

- Bilateral salpingectomy (with or without oophorectomy)

- Surgical hysterectomy

- Bilateral oophorectomy (with or without hysterectomy)

2. Postmenopausal, defined as the following:

- Last menstrual period greater than 12 months prior to Screening without an
alternative medical cause, AND

- Postmenopausal status confirmed by serum Follicle-stimulating hormone (FSH)
concentration at Screening > 40 mIU/mL

3. Female participants of childbearing potential must use at least one of the
following protocol-specified highly effective methods of birth control, AND must
agree to use barrier contraception (male condom) during heterosexual intercourse,
from the time of Screening until at least 90 days after EQ143 treatment:

- Infertile male partner (eg, vasectomy [at least 6 months prior to Screening;
vasectomized partner should be the sole partner of the female participant],
permanently sterile following bilateral orchidectomy, or any other
documented cause of infertility)

- Combined (estrogen and progestogen containing) hormonal contraception (oral,
intravaginal, transdermal, injectable)

- Progestogen-only hormonal contraception (oral, injectable, implantable)

- Implantable device (implantable rod or intrauterine device)

- Bilateral tubal occlusion Alternatively, females of childbearing potential
must practice complete abstinence (defined as refraining from heterosexual
intercourse when this is in line with the preferred and usual lifestyle of
the participant; periodic abstinence and withdrawal are not acceptable) from
Screening until at least 90 days after EQ143 treatment. It is not necessary
to use any other method of contraception when complete abstinence is
elected. Women of childbearing potential (WOCBP) who choose complete
abstinence must continue to have pregnancy tests as per protocol. The
reliability of sexual abstinence needs to be evaluated by the Investigator
in relation to the duration of the clinical trial and the preferred and
usual lifestyle of the participant.

Participants must agree to not donate sperm or ova from time of EQ143 administration
until 90 days after EQ143 treatment.

6. Male participants must agree to utilize a highly effective method of contraception
(condom) during heterosexual intercourse from CRU admission until 12 weeks following
the final Follow-up visit on Day 10 and must refrain from donating sperm for this same
period;

7. Considered healthy by the Investigator, based on participant's reported medical
history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital
signs;

8. Willing and able to adhere to study restrictions and to be confined at the clinical
research center;

9. Participants willing to defer receiving prophylactic live immunizations during the
duration of the study. Participants may receive vaccination for SARS-CoV-2 at the
discretion of the Investigator as soon as they are eligible, and a vaccine is
available. If and when possible, the inactivated mRNA-based vaccines are recommended.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
A participant who meets any of the following exclusion criteria must be excluded from the
study:

1. Inability to attend all the study visits or comply with study procedures;

2. Evidence of clinically significant history of gastrointestinal, musculoskeletal,
endocrine, hematologic, renal, hepatic, neurologic, ophthalmic, immunologic, lipid
metabolism disorders, drug hypersensitivity, psychiatric disease and abnormalities or
any known history of any gastrointestinal surgery or cholecystectomy that could impact
the PK of EQ143 as determined by the Investigator or Sponsor;

3. Evidence of clinically significant history of cardiovascular disease, including
myocardial infarction, unstable angina, Torsade de Pointes, clinically significant
arrhythmias (including sustained ventricular tachyarrhythmia and ventricular
fibrillation), symptomatic congestive heart failure (New York Heart Association class
III or IV), cerebrovascular accident, transient ischemic attack, or symptomatic
pulmonary embolism or other clinically significant episode of thromboembolic disease;

4. A history of additional risk factors for Torsade de Pointes (eg, heart failure,
hypokalemia, family history of Long QT Syndrome);

5. Evidence of clinically significant history of bronchopulmonary disease, including
interstitial lung disease (ILD), drug induced ILD, radiation pneumonia requiring
steroid treatment and clinical evidence of active ILD;

6. Female participants of childbearing potential except as permitted by 5 a, b, or c
under inclusion criteria;

7. Hospital admission or major surgery within 3 months prior to Screening;

8. A history of prescription drug abuse, or illicit drug use within 6 months prior to
Screening;

9. A history of alcohol abuse according to medical history within 6 months prior to
Screening;

10. A history of organ transplant, including history of bone marrow transplant;

11. Taken any prescription medications (excluding contraceptives) within 14 days or 5
half-lives (whichever is longer) of the study dose or taken an investigational drug
within 3 months or 5 half-lives, whichever is longer, from the Screening date;

12. Evidence of hypertension stage 2, defined as a systolic BP > 140 mmHg and a diastolic
BP > 90 mmHg at Screening. Blood pressure measurement should be performed in
triplicate if initial results exceed these values, and the average value should be
used to determine eligibility;

13. Fever (body temperature > 38°C) or symptomatic viral or bacterial infection within 2
weeks prior to Screening. PCR testing for SARS-CoV-2 infection will be performed in
accordance with local guidelines (health authorities, Institutional Review
Boards/Independent Ethics Committees, and study center policies) and at the discretion
of the Investigator, if required;

14. Any of the following ECG criteria at Screening or Admission:

1. PR interval > 220 ms or < 110 ms;

2. QRS interval > 120 ms;

3. QTcF interval > 450 ms in males and > 480 ms in females;

4. A marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of
a QTc interval > 450 ms)

5. ST segment elevation or depression considered to be clinically significant by the
Investigator or designee;

6. T-wave abnormalities considered to be clinically significant by the Investigator
or designee; If the QTcF interval exceeds 450 ms (males) or 480 ms (females), or
the QRS interval exceeds 120 ms, the ECG should be repeated in triplicate and the
average of the 3 QTcF or QRS values should be used to determine the patient's
eligibility.

15. Impaired renal function as determined by Investigator following review of clinical
laboratory test results (ie, estimated glomerular filtration rate [eGFR] less than 90
mL/min/1.73m2, as calculated using the method standard for the institution);

16. Any of the following safety laboratory findings at Screening or Admission:

1. Absolute neutrophil count < 1.5 × 109/L

2. Platelet count < 100 × 109/L

3. Hemoglobin < 90 g/L (< 9 g/dL)

4. International Normalized Ratio (INR) > 1.5

5. Creatinine outside normal limits

17. Positive blood screen for HIV, positive Hepatitis B core antibody (HBcAb) and positive
Hepatitis B surface antigen (HBsAg), positive Hepatitis C virus antibody (HCV Ab) and
positive HCV polymerase chain reaction (PCR), positive Hepatitis A antibody. Note: A
positive HCV Ab with negative HCV PCR, positive HBcAb with negative HBsAg, positive
Hepatitis A virus with negative immunoglobulin M (IgM) will be eligible;

18. Participants with major clinical infections within 3 months prior to Screening or any
symptoms of infection within 7 days prior to Screening (not applicable to participants
with cutaneous fungal infection);

19. Participants who have received live vaccines or attenuated vaccines within 1 month
before dosing. Participants may receive vaccination for SARS-CoV-2 at the discretion
of the Investigator as soon as they are eligible and a vaccine available. If and when
possible, the inactivated mRNA-based vaccines are recommended;

20. Donated or lost > 500ml of blood in the previous 3 months prior to Screening;

21. Any liver function panel analyte (LFT) value > 1.5 × upper limits of normal reference
range (ULN) which includes aspartate aminotransferase (AST), alanine aminotransferase
(ALT), Alkaline Phosphatase (ALP), and gamma-glutamyl transferase (GGT) at Screening
or at Admission. Bilirubin should be > ULN, or > 3 × ULN for participants with
well-documented Gilbert's Syndrome;

22. Participants who have taken a special diet (including dragon fruit, mango, grapefruit,
starfruit, Seville oranges etc.) or other factors affecting drug absorption,
distribution, metabolism, and excretion within 48 hours before taking EQ143;

23. Use of prescription medications (excluding contraceptives) within 14 days, over the
counter (OTC) medication within 7 days, and herbal supplements, dietary supplements,
protein powders, and fish oil within 7 days prior to dosing (Note: Use of
acetaminophen/paracetamol at < 2 g/day is permitted until 24 hours prior to dosing.
Any other nonsteroidal anti-inflammatory drugs [NSAIDs]/antihistamines if permitted
can be discussed on a case-by-case basis by the Medical Monitor [MM] and Sponsor).
Prophylactic medication may continue as long as this is approved by the MM and Sponsor
prior to inclusion;

24. Participants who have dysphagia or any history of gastrointestinal diseases that
affect drug absorption or have undergone operations that affect drug absorption;

25. Participants with any other active malignancy within 5 years prior to enrollment,
except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in
situ;

26. Any condition or finding that in the opinion of the Principal Investigator or designee
would put the participant or study conduct at risk if the participant were to
participate in the study.

27. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at
any time during the study, including the Follow-up period.

28. Participants who are regular smokers, ie, smoke more than five cigarettes per day or
more than 10 packets per year and are not willing to refrain from smoking from 48
hours before EQ143 administration through to the final Follow-up visit on Day 10.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/10/2021
Sample size
Target
Accrual to date
Final
45
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Wisconsin
Country [2] 0 0
New Zealand
State/province [2] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
EQRx, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label and uncontrolled study to evaluate the comparative PK of EQ143
following oral single dose administration in adult healthy volunteers different racial and
ethnic populations.

A total of one (1) single dose cohort is planned at 110 mg of EQ143. EQ143 is an approved
therapy in China at the 110 mg dose for the treatment of patients with Epidermal Growth
Factor Receptor (EGFR) T790Mmutation-positive, metastatic non-small cell lung cancer (NSCLC),
who have progressed during or after EGFR tyrosine kinase inhibitor (TKI) therapy.

A total of 45 (15 Caucasian, 8 Black/African American and 7 Hispanic/Latino, and 15 ethnic
Chinese)
Trial website
https://clinicaltrials.gov/ct2/show/NCT04969965
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04969965